Skip to main content

ECOR

Stock
Health Care
Medical Devices

Performance overview

ECOR Price
Price Chart

Forward-looking statistics

Beta
0.82
Risk
72.97%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

electrocore is, a us based electroceutical healthcare company, which is developing a range of non-invasive vagus nerve stimulation (nvns) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electrocore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the us (head office), germany (german and european head office), uk, italy, australia, and canada.

Company info

SectorHealth Care
IndustryMedical Devices
Employees67
Market cap$39.3M

Fundamentals

Enterprise value$35.6M
Revenue$26.5M
Revenue per employee
Profit margin-46.24%
Debt to equity95.85

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.53
Dividend per share
Revenue per share$3.35
Avg trading volume (30 day)$549K
Avg trading volume (10 day)$530K
Put-call ratio

Macro factor sensitivity

Growth+2.3
Credit+3.5
Liquidity0.0
Inflation-1.6
Commodities-1.8
Interest Rates-5.1

Valuation

Dividend yield0.00%
PEG Ratio-11.11
Price to sales1.71
P/E Ratio-11.11
Enterprise Value to Revenue1.35
Price to book10.39

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend day

News

ElectroCore, Inc. (ECOR) Reports Q1 Loss, Misses Revenue Estimates

ElectroCore, Inc. (ECOR) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.53 per share a year ago.

Zacks Investment Research (May 7, 2025)
ElectroCore's Vagus Nerve Stimulator Wins Breakthrough Device Tag For Stress Disorder

The FDA has granted Breakthrough Designation to ElectroCore Inc's (NASDAQ:ECOR) gammaCore nVNS device for posttraumatic stress disorder (PTSD). The device showed a reduction of symptoms of PTSD by 31% when compared to sham.

Benzinga (January 12, 2022)
Top Stocks To Short As Dow Surges From Boeing Gains

As the virus spreads, if you're looking to bet against the market or hedge, our deep learning algorithms paired with out Artificial Intelligence ('AI') data has some Top Shorts named for you today.

Forbes (June 29, 2020)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free